Drug Database
Back to search

Poland· PL-100130930

Clemastinum Hasco

A clemastine product containing clemastinum, registered in Poland by Przedsiębiorstwo Produkcji Farmaceutycznej HASCO-LEK S.A.. The same ATC class is registered in 11 of our 19 countries.

ATC R06AA04

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedClemastinum HascoATCR06AA04REGISTER NO.PL-100130930PACKS LISTED3CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about clemastinumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Clemastine is registered in 11 of 19 countries.

Countries holding a registration under ATC R06AA04 (clemastine), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 6 of them publish a price we can compare per daily dose
Search clemastine products by name

Clemastine · ATC R06AA04

11 / 19 countries

  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Clemastinum
Manufacturer
Przedsiębiorstwo Produkcji Farmaceutycznej HASCO-LEK S.A.
Country
Poland (PL)
ATC code
R06AA04
ATC class
Clemastine
Defined daily dose
2 mg, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 3

  • gtin
    05909991107413
  • gtin
    05909991107420
  • gtin
    05909991107437

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

321 interactions on record for clemastine.

Graded by severity as the source publishes them — 9 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check clemastine against other medicinesHow interaction checks work

Clemastine · interactions on record

321 records

  • 9 severe
  • 309 moderate
  • 3 minor

Most severe, free to view

  • Potassium chlorideA12BA01severe
  • Potassium citrateA12BA02severe
  • Potassium chlorideB05XA01severe
  • Sodium oxybateN01AX11severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Clemastine in 10 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All clemastine products

Authorised across Europe · EMA

The same active substance is authorised in 12 EEA countries. Names it is sold under:

  • Germany · Tavegil, Tavegil Tabletten
  • Denmark · Clemastine Macure
  • Estonia · Tavegyl
  • Finland · Clemastine Macure
  • United Kingdom (Northern Ireland) · Tavegil
  • Iceland · Tavegyl
  • Lithuania · Clemastinum Pph, Tavegyl
  • Latvia · Tavegyl
  • Netherlands · Clemastine Macure, Clemastine Milstein
  • Norway · Clemastine Macure
  • Portugal · Tavégyl, Tavist
  • Sweden · Clemastine Macure, Tavegyl

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/74e0a905-23bb-49a6-8df9-8c5bf9b6ae47
GET /v1/drugs/74e0a905-23bb-49a6-8df9-8c5bf9b6ae47?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki",
  "source": "urpl",
  "strength": "1 mg",
  "packaging": "05909991107413 ¦ Rp ¦ 25387\n7 tabl.\n05909991107420 ¦ Rp ¦ 25388\n15 tabl.\n05909991107437 ¦ Rp ¦ 25389\n30 tabl.",
  "substance": "Clemastini fumaras 1.34 mg",
  "common_name": "Clemastinum",
  "pl_product_id": "100130930",
  "pozwolenie_nr": "11074",
  "auth_procedure": "NAR",
  "authorisation_validity": "Bezterminowe"
}
API referenceMCP serverPlans

See everything about clemastine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console